From: Impact of continued administration of tolvaptan on cirrhotic patients with ascites
Total (n = 170) | Discontinued* (n = 90) | Continued** (n = 37) | p-value * vs. ** | |
---|---|---|---|---|
Age (years) | 63 (21–90) | 60 (21–85) | 63 (22–90) | 0.28 |
Sex (% of males) | 95/170 (56%) | 47/90 (52%) | 23/37 (62%) | 0.31 |
BW (kg) | 61.9 (34.4–143.6) | 61.6 (37.4–98.9) | 62.9 (34.4–143.6) | 0.48 |
BW after 1 week (kg) | 60.9 (32.7–136.2) | 61.5 (36.3–103.8) | 61.0 (32.7–136.2) | 0.75 |
BW reduction after 1 week (kg) | 1.5 (−6.2–17.2) | 1.1 (−6.2–7.5) | 2.0 (−3.4–17.2) | 0.03 |
Urine volume (mL) | 1595 (120–6630) | 1450 (120–6630) | 1690 (195–4460) | 0.77 |
Etiology of liver disease (%) | 0.07 | |||
HCV | 48 (28%) | 28 (31%) | 6 (16%) | |
HBV | 12 (7%) | 4 (4%) | 4 (11%) | |
ALD | 48 (28%) | 22 (24%) | 15 (41%) | |
NAFLD | 19 (11%) | 7 (8%) | 5 (14%) | |
PBC | 17 (10%) | 7 (8%) | 4 (11%) | |
Others | 31 (18%) | 24 (27%) | 4 (11%) | |
Complication (%) | ||||
Gastroesophageal varices | 109/160 (68%) | 62/82 (76%) | 21/37 (57%) | 0.04 |
Hepatocellular carcinoma | 54/170 (32%) | 26/90 (29%) | 13/37 (35%) | 0.51 |
Hepatic encephalopathy | 46/170 (27%) | 33/90 (37%) | 8/37 (22%) | 0.10 |
Diuretics | ||||
Furosemide dose (mg/day) | 20 (0–160) | 20 (0–120) | 20 (0–80) | 0.48 |
Spironolactone dose (mg/day) | 50 (0–400) | 50 (0–400) | 50 (0–150) | 0.24 |
Branched-chain amino acid (%) | 150/170 (88%) | 76/90 (84%) | 35/37 (95%) | 0.12 |
CART or drainage (%) | 84/170 (49%) | 47/90 (52%) | 15/37 (41%) | 0.37 |
Denver shunt | 6 (4%) | 1 (1%) | 3 (8%) | 0.04 |
Laboratory data | ||||
Albumin (g/dL) | 2.4 (1.5–4.2) | 2.4 (1.6–3.6) | 2.6 (1.7–4.2) | 0.03 |
Total bilirubin (mg/dL) | 1.9 (0.3–52.4) | 2.2 (0.3–52.4) | 2.0 (0.4–21.7) | < 0.01 |
Aspartate aminotransferase (U/L) | 48 (10–551) | 52 (12–551) | 42 (13–171) | 0.06 |
Alanine aminotransferase (U/L) | 28 (3–381) | 29 (3–381) | 29 (7–144) | 0.53 |
γ-Glutamyl transpeptidase (U/L) | 49 (9–269) | 52 (9–269) | 48 (9–229) | 0.28 |
Platelet count (×104/μL) | 8.8 (1.5–62.7) | 8.8 (2.1–62.7) | 7.6 (1.5–23.9) | 0.10 |
Prothrombin time (PT%) | 55.6 (16.3–90.3) | 52.5 (16.3–89.0) | 54.5 (19.5–90.3) | 0.22 |
PT/INR | 1.31 (0.98–3.17) | 1.33 (1.04–3.17) | 1.32 (0.98–2.84) | 0.36 |
Ammonia (μg/dL) | 66 (16–269) | 60 (24–212) | 85 (25–269) | 0.11 |
α-fetoprotein (ng/mL) | 4 (1–142,010) | 4 (1–142,010) | 4 (1–210) | 0.13 |
Des-gamma-carboxy (mAU/mL) | 68 (3–357,790) | 73 (5–357,790) | 27 (3–4994) | 0.26 |
Blood urea nitrogen (mg/dL) | 20.9 (5.5–125.3) | 22.5 (5.8–64.3) | 23.2 (6.0–63.3) | 0.86 |
Creatinine (mg/dL) | 0.99 (0.20–3.30) | 1.00 (0.20–2.87) | 1.04 (0.44–3.30) | 0.28 |
eGFR (mL/min/1.73 m2) | 53.9 (14.9–250.6) | 53.1 (14.9–250.6) | 49.5 (16.8–107.2) | 0.06 |
Serum sodium (mEq/L) | 136 (118–145) | 135 (118–143) | 137 (122–145) | 0.01 |
Modified Child-Pugh (CP) score | 11 (6–14) | 11 (8–14) | 11 (8–13) | 0.05 |
MELD score | 12 (1–37) | 14 (1–37) | 12 (2–29) | 0.53 |